Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials
Author:
Affiliation:
1. Center for Pharmacometrics and Systems Pharmacology; University of Florida; Orlando FL USA
2. Abbvie, Inc.; North Chicago IL USA
Funder
AbbVie
Publisher
Wiley
Subject
Cancer Research,Oncology,Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2514/fullpdf
Reference36 articles.
1. United States Food and Drug Administration 2007 https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf
2. Endpoints in cancer clinical trials;Fiteni;J Visc Surg,2014
3. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology;Sherrill;OncoTargets and Therapy,2012
4. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data;Cartier;Oncology Research and Treatment,2015
5. Minimal residual disease as a potential surrogate end point--lingering questions;Gormley;JAMA Oncol,2017
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA;American Journal of Hematology;2024-01-31
2. Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma;Future Oncology;2023-04-21
3. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma;Frontiers in Immunology;2022-09-02
4. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2022-09
5. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3